Duchenne Muscular Dystrophy (DMD) – Epidemiology Insights and Forecast Report – 2020 To 2040
Duchenne Muscular Dystrophy (DMD) Epidemiology Insights
Thelansis’s “Duchenne
Muscular Dystrophy (DMD) Epidemiology Insights and Forecast Report – 2020 To
2040″ provides an analysis of disease burden, characterized by disease
definition, prevalence, incidence, diagnosed cases, severity, comorbidities,
and clinical manifestations. Potential patient flow dynamics in disease burden
are driven by shifts in demographic indicators and their correlation with age
and gender distribution over time. Changes in the reported cases and long-term
survival of patients may depend on diet, lifestyle, comorbid conditions, and
the availability of interventions or therapies.
Duchenne
Muscular Dystrophy (DMD) Overview
Duchenne muscular dystrophy (DMD) is a
rare genetic disorder characterized by the progressive weakening and wasting of
muscles, affecting skeletal, smooth, and cardiac muscle tissues. The underlying
cause of muscle damage is the absence of the sarcolemmal protein dystrophin due
to variations in the DMD gene located on Xp21.2. Symptoms of DMD typically
manifest in early childhood, with affected boys often experiencing delayed
walking, typically after 18 months, along with speech and developmental delays.
Individuals with DMD may also face autism and behavioral issues, including
ADHD, anxiety, and obsessive-compulsive disorder. Unfortunately, untreated
children with DMD rarely achieve the ability to run or jump. The condition
progresses rapidly, leading to a characteristic waddling gait and a positive
Gowers’ sign.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables
format and updates*:
- Access to an interactive epidemiology
platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional
findings
- Country-specific
findings
- Others*: regular updates,
customizations, epidemiologist support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the content. Countries, subpopulations, and years of forecast can be
customized as per client requirements.
Key business
questions answered:
- 20-year historical and forecast data
(2020–2040)
- Disease definition based on globally
accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage
by year and geography
- Detailed segmentation by age, gender,
subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g.,
staging/classification/severity)
Insights
driven by robust research and estimates:
- Published literature (e.g.,
peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR
datasets
- Proprietary mathematical models
(e.g., incidence-survival model;
incidence- recurrence/progression-survival model)
Read more: Duchenne Muscular Dystrophy (DMD) – Epidemiology
Insights and Forecast Report – 2020 To 2040
Comments
Post a Comment